Greenwich LifeSciences (GLSI) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 136.2% versus a loss of 38.6%. Over five years, GLSI leads with a -41.8% price change compared with -86.1% for RLMD. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $279.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | RLMD |
|---|---|---|
| Share price | $19.25 | $2.62 |
| Market cap | $282.56M | $279.54M |
| 1-day change | -2.73% | -15.76% |
| YTD return | -8.38% | -45.76% |
| 1-year return | +136.20% | -38.64% |
| 5-year return | -41.84% | -86.09% |
| EPS (TTM) | $-1.63 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-19.36M | $-57.39M |
| 52-week high | $34.10 | $8.00 |
| 52-week low | $7.78 | $2.60 |
| Distance from 52-week high | -43.55% | -67.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +198.70% | +310.31% |
| Average volume | 160.76K | 1.45M |
| Shares outstanding | 14.68M | 106.69M |
| Employees | — | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed RLMD by 174.8 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
GLSI vs RLMD FAQ
Which is bigger, Greenwich LifeSciences or Relmada Therapeutics?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $279.54M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, GLSI or RLMD?
GLSI returned +136.20% over the past 12 months, compared with -38.64% for RLMD (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.